Immunotherapy plus chemo shows promise for tough uterine cancer

NCT ID NCT07108270

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether the immunotherapy drug dostarlimab, given together with standard chemotherapy (carboplatin and paclitaxel), can help Chinese patients with a specific genetic type of advanced or recurrent endometrial cancer. The study will enroll 30 participants and measure how many have a lasting response for at least 12 months. The goal is to find a more effective treatment for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dostarlimab (an immunotherapy drug) combined with chemotherapy drugs carboplatin and paclitaxel
What this could lead to: If successful, this could offer a new treatment option for Chinese patients with a specific type of advanced or recurrent endometrial cancer.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination therapy may cause side effects like immune reactions or typical chemo toxicities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS, ENDOMETRIAL

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.